HomeOur ProjectsHepC in NYC

HepC in NYC

Overview:

Addressing HCV-related hepatocellular carcinoma: the current and future epidemics.” Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% will develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science – research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses – to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into account limited resources and underlying epidemiologic and social network features. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

Featured News

Authors: Holly Hagan, Joshua Neuer, Ashly E Jordan, Don C Des Jarlais, Jennifer Wu, Kirk Dombrowski, Bilal Khan, R Scott Braithwaite and Jason Kessler Title  : Hepatitis C virus infection among HIV-positive men who have sex with men: Protocol for a systematic review and meta-analysis Journal: Systematic Reviews MS     : 1739556256122659

PI: Holly Hagan (NYU) Investigators: Bilal Khan and Kirk Dombrowski National Institute of Drug Abuse (NIH) has awarded funding to the “Addressing HCV-related hepatocellular carcinoma: the current and future epidemics” project (R01 DA034637-01). Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people

Project Details

Addressing HCV-related hepatocellular carcinoma: the current and future epidemics.” Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% will develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science – research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses – to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into account limited resources and underlying epidemiologic and social network features. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

“Addressing HCV-related hepatocellular carcinoma: the current and future epidemics” is funded by the National Institute of Drug Abuse, R01 DA034637-01 under the direction of Holly Hagan, Principal Investigator, New York University, from July 2013-June 2017.[

The leader of this work at REACH is Kirk Dombrowski, who will work closely with Bilal Khan, and Mohamed Saad at CUNY to implement the simulation portion of the project using the MABUSE platform.